London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect. Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS) , when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading...

This story was reported by Business | The Guardian. EUROPES curates Europe's most relevant coverage — read the full report at the original source.